Rituximab. Chronic lymphoid leukaemia: no decisive advantage.

  • Published 2010 in Prescrire international


When treatment is needed for patients with symptomatic chronic lymphoid leukaemia, the standard first-line treatment is oral chlorambucil. Fludarabine has been used more as a second-line option. Rituximab has been authorised for use in both first-line and second-line therapy. We found no randomised trials comparing rituximab versus either chlorambucil or… (More)


  • Presentations referencing similar topics